Novo Nordisk aims to bring triple-G obesity injection to market by 2030

Novo Nordisk said it plans to launch a triple‑G obesity injection by 2030. The drug would combine agonist activity at the GLP‑1, GIP and glucagon receptors, a class that researchers believe could be the most effective for weight loss.

The company highlighted growing data that supports the triple‑G approach, noting that early studies suggest stronger efficacy than existing GLP‑1‑only therapies. While Novo Nordisk is setting the timeline, it acknowledges that other firms, including Eli Lilly, are also advancing similar candidates.

The announcement underscores the competitive race to develop next‑generation obesity treatments, with the market expected to respond strongly if the triple‑G drugs deliver on their promise.